Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: Six-month follow-up from the electronic schizophrenia treatment adherence registry in Latin America

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 19-26

  Apiquian, Rogelio ^a   Córdoba, Rodrigo ^b   Louzã, Mario ^c  

^a University of the Americas   (Mexico)

^b Nervous system research center cisne   (Colombia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Latin America; Long acting; Risperidone; Schizoaffective disorder; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LONG ACTING DRUG; LORAZEPAM; OLANZAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID;

ADULT; AKINESIA; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOBAL IMPRESSION OF FUNCTIONING; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLISM; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONAL AND SOCIAL PERFORMANCE; PRESCRIPTION; PSYCHOSIS; REGISTER; RELAPSE; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL INTERACTION; SOUTH AND CENTRAL AMERICA; UNEMPLOYMENT;

EID: 79951609794     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S15911     Document Type: Article

References (64)

1. Beasley CMJ, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol-ogy. 1996;14(2):111-123.
2. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol. 1994;14(3):201-204.
3. Barkic J, Filakovic P, Radanovic-Grguric L, et al. The infuence of risperidone on cognitive functions in schizophrenia. Coll Antropol. 2003;27 Suppl 1:111-118.
4. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647.
5. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004;66(2-3):143-150.
6. Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: Comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002; 12(4):305-310.
7. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisul-pride Study Group. Int Clin Psychopharmacol. 2000;15(1):13-22.
8. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. Am J Psychiatry. 2007;164(3):428-436.
9. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373(9657):31-41.
10. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006;1(1):47-56.
11. Blackwell B. Treatment adherence. Br J Psychiatry. 1976; 129:513-531.
12. Wright EC. Non-compliance - or how many aunts has Matilda? Lancet. 1993;342(8876):909-913.
13. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46(10): 1049-1054.
14. Weiden PJ. Discontinuing and switching antipsychotic medications: Understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68 Suppl 1:12-19.
15. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159(1):103-108.
16. Lieberman JA, Alvir JM, Woerner M, et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull. 1992;18(3):351-371.
17. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544-549.
18. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
19. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85.
20. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57 Suppl 9:5-9.
21. Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl. 1989;15:1-46.
22. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59 Suppl 3:21-25.
23. Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. Br J Clin Psychol. 2000;39 Pt 3: 287-295.
24. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699.
25. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639.
26. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-180.
27. Remington GJ, Adams ME. Depot neuroleptic therapy: Clinical considerations. Can J Psychiatry. 1995;40(3 Suppl 1):S5-S11.
28. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47(5): 741-773.
29. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998;24(1):11-20.
30. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296.
31. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23 Suppl 1:75-89.
32. Annemans L. Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us? Pharmacoeconomics. 2005;23 Suppl 1:1-2.
33. Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: A prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2009;70(2): 196-200.
34. Lindenmayer JP, Parak M, Gorman JM. Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response. J Psychiatr Pract. 2006;12(1):55-57.
35. Peuskens J, Olivares JM, Pecenak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501-509.
36. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003(416):16-23.
37. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
38. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4): 323-329.
39. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257.
40. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003; 160(6):1125-1132.
41. Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq ZU, Saleh BT. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Curr Med Res Opin. 2003;19(4): 298-305.
42. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multi center, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8): 1084-1089.
43. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting inject-able in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005;20(3):121-130.
44. Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting inject-able risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 2007;40(6):257-263.
45. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting inject-able risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004; 19(4):241-249.
46. Schmauss M, Sacchetti E, Kahn JP, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol. 2007;22(2):85-92.
47. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review. Prim Care Companion J Clin Psychiatry. 2009;11(4):147-154.
48. Fleischhacker WW, Oehl MA, Hummer M. Factors infuencing compliance in schizophrenia patients. J Clin Psychiatry. 2003;64 Suppl 16: 10-13.
49. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
50. Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr. 2005;27(3):178-184.
51. Bebbington PE. The content and context of compliance. Int Clin Psy-chopharmacol. 1995;9 Suppl 5:41-50.
52. Chue P. Long-acting risperidone injection: Efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsy-chiatr Dis Treat. 2007;3(1):13-39.
53. Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: Depot versus oral. J Clin Psychiatry. 2008;69(10):1548-1556.
54. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005;56(3):273-282.
55. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry. 2005;187:131-136.
56. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004;65(4):531-536.
57. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: Costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346-351.
58. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21(12):2017-2028.
59. Vehof J, Postma MJ, Bruggeman R, et al. Predictors for starting depot administration of risperidone in chronic users of antipsychotics. J Clin Psychopharmacol. 2008;28(6):625-630.
60. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J Clin Psychopharmacol. 2008;28(2):210-213.
61. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325-331.
62. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol. 2005;19(Suppl 5):5-14.
63. Lambert T, Brennan A, Castle D, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract. 2003;9(3):252-260.
64. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand. 1997;95(6):464-468.